Back to News
Market Impact: 0.15
Meta, JPMorgan, West Pharmaceutical And More: CNBC's ‘Final Trades'
Source: benzinga.com
Analyst Insights
Joseph M. Terranova, senior managing director at Virtus Investment Partners, said on CNBC’s “Halftime Report Final Trades” that he likes West Pharmaceutical Services (NYSE: WST). The article provides no supporting rationale, price target, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
WST0.30
More News
- Dell stock plunges 11%, leading data center sell-off on concerns about 'enterprise AI timing'
- AI infrastructure stocks tumble. Here's a few reasons for the sell-off
- A second major Wall Street bank this week is telling clients to cash in tech stocks. Here's why
- Why Dell’s stock was one of the S&P 500’s biggest laggards on Wednesday
- These stocks offer some of the best risk-adjusted upside on Wall Street
- Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Evaluate AI Report Writers for Financial Analysis
- Weekly Update: Sector Analysis, Improvements on Research Data, and Performance Enhancements